Tin tức & Cập nhật
Xem bài viết Ung thư
Xem

Cancer therapy takes a toll on women’s sexual health
In women being treated for cervical cancer, chemotherapy and radiotherapy appear to have a substantial and lasting negative effect on sexual health, including satisfaction and desire, as shown in a descriptive cross-sectional study conducted in Brazil.

Letrozole-abemaciclib plus metformin shows promise in endometrial cancer treatment
Adding metformin to letrozole and abemaciclib does not cause serious safety concerns and may even encourage favourable responses among patients with oestrogen receptor (ER)-positive recurrent endometrial cancer (EC), according to a phase II study presented at SGO 2025.

LHRH analogues vs tE2 patches: Which work best for prostate cancer?
The use of transdermal oestradiol (tE2) or oestrogen patches helps suppress testosterone and prostate-specific antigen (PSA) in men with locally advanced prostate cancer, with similar efficacy to that of luteinizing hormone-releasing hormone (LHRH) analogues, reports a study presented at EAU 2025.

SC vs IV pembrolizumab: Which route is better for metastatic NSCLC?
In patients with treatment-naive metastatic nonsmall cell lung cancer (NSCLC), subcutaneous (SC) pembrolizumab (pembro) demonstrates comparable efficacy to that of intravenous (IV) pembro as regards overall exposure and trough concentration, reports a study presented at ELCC 2025.

Neoadjuvant chemo plus durvalumab improves survival in NSCLC
The addition of durvalumab to neoadjuvant chemotherapy with cisplatin and docetaxel results in better survival rates among patients with resectable nonsmall cell lung cancer (NSCLC), according to a study presented at ELCC 2025.




